MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone”) (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle

“The Company is successfully achieving key milestones for our investigational ExoPTEN drug and, in parallel, developing an exosome therapy platform that can be widely used by the medical industry to address many other illnesses,” Dr. Lior Shaltiel, CEO of NurExone. “We believe that the hybrid product-platform model will drive revenue

TORONTO and TEL AVIV, Israel, May 16, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone“) (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that the Company has received an issue notification from the United States

Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 12, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC (“Litchfield”) to

Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 8, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone“), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options (“Options“) and

NurExone’s research and development investment grew by 143.9% from US$0.57 million in 2021 to US$1.39 million in 2022, due to increased activity in preclinical trials in the Company’s labs. The Company recently disclosed additional results from an internal preclinical study of its investigational drug, ExoPTEN, which demonstrated effective treatment of 75%

The Company’s most recent preclinical trials, that have taken place over 10 weeks in NurExone’s labs in Israel, have proven that its experimental drug ExoPTEN caused 75% of rat subjects in the study to regain hind limb reflex, some motor function, and sensory control. These rats, who regained function, also

The current study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection (i.e. complete severing) of the spinal cord.   Read More >>>

NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes. This combination aims to position the company ahead of its competitors in terms of effectiveness and efficiency. Read More >>>

The Patent discloses and claims groundbreaking inventions and methods in exosome technology, such as the pharmaceutical compositions comprising extracellular vesicles including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor as well as a method for treating neuronal injury or damage, including intranasal administration. Read More